| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/07/2004 | EP1405911A1 Interaction trap systems for detecting protein interactions |
| 04/07/2004 | EP1405646A2 Pharmaceutically acceptable salts of local anaesthetics with anti-inflammatory compounds and methods for preparing the same |
| 04/07/2004 | EP1405644A1 Tissue-specific transporter inhibitor |
| 04/07/2004 | EP1405639A1 Use of sodium channel blocking compounds and aspirin in manufacturing drugs for producing synergistic analgesic effect in mammals |
| 04/07/2004 | EP1405083A2 Natural ligand of gpcr chemr23 and uses thereof |
| 04/07/2004 | EP1405082A2 Method for identifying compounds for the therapy of aging of the cardiovascular system |
| 04/07/2004 | EP1405079A2 Modulation of the interaction between evh1 domains |
| 04/07/2004 | EP1405074A2 P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 04/07/2004 | EP1404871A2 Method for treatment of cancer associated with elevated her 2 levels |
| 04/07/2004 | EP1404868A2 Compositions and methods relating to osteoarthritis |
| 04/07/2004 | EP1404864A2 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways |
| 04/07/2004 | EP1404863A1 PIBs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
| 04/07/2004 | EP1404831A2 Type 2 cytokine receptor and nucleic acids encoding same |
| 04/07/2004 | EP1404718A2 Inhibitors of memapsin 2 and use thereof |
| 04/07/2004 | EP1404714A2 Nuclear hormone receptor ligand binding domain |
| 04/07/2004 | EP1404710A2 Identification of ses-3 (spr-5) in c. elegans and the uses of the same |
| 04/07/2004 | EP1404706A2 Mycobacterial antigens expressed during latency |
| 04/07/2004 | EP1404704A1 Bridged bicyclic serine protease inhibitors |
| 04/07/2004 | EP1404703A2 G-protein coupled receptors |
| 04/07/2004 | EP1404672A1 Tyrosine kinase inhibitors |
| 04/07/2004 | EP1404669A2 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| 04/07/2004 | EP1404654A2 Calcilytic compounds |
| 04/07/2004 | EP1404374A1 Slc2as as modifiers of the p53 pathway and methods of use |
| 04/07/2004 | EP1404369A1 Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases |
| 04/07/2004 | EP1404367A2 Use of polyclonal anti-hiv goat serum as a therapeutic agent |
| 04/07/2004 | EP1404365A2 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy |
| 04/07/2004 | EP1404364A1 Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity |
| 04/07/2004 | EP1404359A2 Methods of treatment involving human mda-7 |
| 04/07/2004 | EP1404356A2 Cd10-activated prodrug compounds |
| 04/07/2004 | EP1404350A2 Proteins associated with cell growth, differentiation, and death |
| 04/07/2004 | EP1404347A2 4'-substituded nucleosides for the treatment of diseases mediated by the hepatitis c virus |
| 04/07/2004 | EP1404345A2 Skin-permeable selective cyclooxygenase-2 inhibitor composition |
| 04/07/2004 | EP1404344A2 Bone anabolic compounds and methods of use |
| 04/07/2004 | EP1404342A1 Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics |
| 04/07/2004 | EP1404341A1 Active substance combination for medicamentous therapy of nicotine dependency |
| 04/07/2004 | EP1404337A2 QUINAZOLINE AND PYRIDO 2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 |
| 04/07/2004 | EP1404334A1 Targeted delivery of bioaffecting compounds for the treatment of cancer |
| 04/07/2004 | EP1404330A1 Substituted 8-arylquinoline pde4 inhibitors |
| 04/07/2004 | EP1404329A1 Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 04/07/2004 | EP1404326A2 Method of treating parkinson's disease |
| 04/07/2004 | EP1404324A2 Prodrugs of gaba analogs, compositions and uses thereof |
| 04/07/2004 | EP1404323A1 Use of methylnaltrexone to treat immune suppression |
| 04/07/2004 | EP1404322A2 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof |
| 04/07/2004 | EP1404320A2 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent for modulating cholinergic function |
| 04/07/2004 | EP1404310A1 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
| 04/07/2004 | EP1404308A1 Treatment of disorders secondary to organic impairments |
| 04/07/2004 | EP1404305A1 Pharmacological preparation made from a nanoparticulate mesomorphous polyelectrolyte lipid complex and at least one active ingredient |
| 04/07/2004 | EP1404303A1 Stable pharmaceutical compositions containing pravastatin |
| 04/07/2004 | EP1404302A1 Pharmaceutical compositions of adsorbates of amorphous drug |
| 04/07/2004 | EP1404301A2 Stable controlled release pharmaceutical compositions containing pravastatin |
| 04/07/2004 | EP1404294A2 Biodegradable polymer composition |
| 04/07/2004 | EP1404268A1 Treating epidermlyosis bullosa with thymosin beta 4 |
| 04/07/2004 | EP1404180A2 Peripheral blood fibrocytes differentiation pathway and migration to wound sites |
| 04/07/2004 | EP1404178A1 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| 04/07/2004 | EP1404174A2 Anti-infective compositions for treating disordered tissue such as cold sores |
| 04/07/2004 | EP1317238A4 Compositions containing a vitamin c component and pigment |
| 04/07/2004 | EP1226433B1 Method for identifying active anti-apoptosis compounds |
| 04/07/2004 | EP1183043B1 Medicament for localised application, containing fibrinogen, thrombin, transglutaminases and proteinase inhibitors |
| 04/07/2004 | EP1150991B1 Compositions for treating inflammatory response |
| 04/07/2004 | EP1128820B1 Pharmaceutical mixture comprising a combination of a profen and other active compounds |
| 04/07/2004 | EP1087783B1 Use of gastrin fragments or synthetic analogs of gastrin for the manufacture of a medicament for the treatment of helicobacter pylori-associated disorders |
| 04/07/2004 | EP0889905B1 Cytokine antagonists and agonists |
| 04/07/2004 | EP0787148B1 Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor |
| 04/07/2004 | EP0712312B1 Suppression of inhibitors |
| 04/07/2004 | CN1487938A Quinuclidine derivatives and their use as M3 antagonists |
| 04/07/2004 | CN1487933A Pyrazole compounds useful as protein kinase inhibitors |
| 04/07/2004 | CN1487837A Novel mixtures of microbial enzymes |
| 04/07/2004 | CN1487833A Pharmaceutical composition for treatment of phimosis using topical corticosteroid |
| 04/07/2004 | CN1487832A Novel method and compositions for local treatment of Meniere's disease, tinnitus and lor hearing loss |
| 04/07/2004 | CN1487822A Anti-adiposis composition based on garlic bulb extracts |
| 04/07/2004 | CN1486745A Stem cell prepn for treating tissue ischemia disease and its prepn process |
| 04/07/2004 | CN1486702A Injection for eliminating wrinkles and scar and its prepn |
| 04/07/2004 | CN1486690A Medicinal salt with local narcosis and antiphlogosis activity and its prepn process |
| 04/07/2004 | CN1144598C Stabilization of compositions containing ACE inhibitors using magnesium oxide |
| 04/07/2004 | CN1144592C Use of camptotheicin derivatives with reduced gastrointestinal toxicity |
| 04/06/2004 | US6717030 Diploid animal cell for use in the treatment of drug addiction, epilepsey, withdrawal syndrome and muscle spasm |
| 04/06/2004 | US6716875 With angiotensin ii antagonist (losartan); angiotensin i converting enzyme inhibitor (captopril); hypotensive agent and for congestive heart failure; renin inhibitor is peptide |
| 04/06/2004 | US6716869 N-(2-(1-amidinopyrrol-3-yl)ethyl)-5,6-dihydroxy-1-(2-(2-methox y-3-sulfatopropionylamino)-3-chloro-4-methylvaleroyl)indole-2-carboxamide |
| 04/06/2004 | US6716868 (-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 04/06/2004 | US6716846 High affinity ligands for nociceptin receptor ORL-1 |
| 04/06/2004 | US6716830 For therapy and prophylaxis of ophthalmic, otic or nasal infections and attendant inflammation |
| 04/06/2004 | US6716829 Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders |
| 04/06/2004 | US6716603 Nucleic acids encoding a chloride channel protein |
| 04/06/2004 | US6716586 Insulin-like growth factor agonist molecules |
| 04/06/2004 | US6716575 Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| 04/06/2004 | US6716441 Article comprising dispensing means with applied release composition including selected skin care active, release agent and barrier protectant; oleaginous, partially transferable to wearer's skin; contains ethoxylated c20-c40 fatty alcohol |
| 04/06/2004 | US6716427 Method for treating hypocalcemia |
| 04/06/2004 | US6716417 Condensation of heated vapor to form aerosol particles |
| 04/06/2004 | US6716416 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an antipsychotic such as olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, etc. |
| 04/06/2004 | US6716415 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of a sedative-hypnotic, such as zaleplon, zolpidem or zopiclone. |
| 04/01/2004 | WO2004027052A1 Th1 cell adoptive immunotherapy |
| 04/01/2004 | WO2004027020A2 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| 04/01/2004 | WO2004026345A1 Control of nitric oxide bioactivity by perfluorocarbons |
| 04/01/2004 | WO2004026341A1 Immunotherapeutic for cancer |
| 04/01/2004 | WO2004026335A1 Pharmaceutical composition comprising carriers for products |
| 04/01/2004 | WO2004026332A1 Methods of increasing platelet and hematopoietic stem cell production |
| 04/01/2004 | WO2004026311A2 Use of specific inhibitors of tyrosine kinases for immunomodulation |
| 04/01/2004 | WO2004026304A1 An inhibitor of the shh signalling patway and a testosterone supressing agent for the treatment of cancer |
| 04/01/2004 | WO2004026300A1 COMBINATIONS OF ATORVASTATIN AND α1, ADRENERGIC RECEPTOR ANTAGONISTS |
| 04/01/2004 | WO2004026296A1 Composition against stress-related diseases |